Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants

• Published in: iScience Vol. 27; no. 9; p. 110728
• Main Authors: Portolés, Antonio, Campins-Artí, Magdalena, Bertrán, María Jesús, Bermejo, Mercedes, Arribas, José Ramón, López, Andrea, Ascaso-del-Rio, Ana, Arana-Arri, Eunate, Fuentes Camps, Inmaculada, Vilella, Anna, Cascajero, Almudena, García-Morales, María Teresa, Castillo de la Osa, María, Pérez Ingidua, Carla, Lora, David, Jiménez-Santana, Paloma, Pino-Rosa, Silvia, De La Torre-Tarazona, Erick, Calonge, Esther, Belda-Iniesta, Cristóbal, Alcamí, José, Frías, Jesús, Carcas, Antonio J., Díez-Fuertes, Francisco, García, Lucía Díaz, García, Elena Ramírez, Meseguer, Enrique Seco, Candón, Alicia Marín, Elizalde, Mikel Urroz, Rosa, Paula de la, García, Marta Sanz, Crespo, Cristina López, Martínez, Vega Mauleón, de Madariaga Castell, Raquel, Prieto-Pérez, Rocío, Laredo, Leonor, Zhu-Huang, Ouhao, Imaz-Ayo, Natale, García de Vicuña, Aitor, Santorcuato, Ana, Exposito, Iraide, de Benito, Sara, Bustinza, Alazne, Gallego, Mikel, García-Vázquez, Dolores, Belén de la Hoz, Ana, Pérez-Nanclares, Gustavo, Aurrekoetxea, Josu, Urrutia, Ines, Martínez-Salazar, Rosa, Orcajo, Janire, Calvo, Begoña, Corcuera, June, Velasco, Olaia, Aguayo, Anibal, Otero-Romero, Susana, Armadans, Lluis, Borras-Bermejo, Blanca, Uriona, Sonia, Santos, José, Pinós, Laia, Camacho, Lina, Riera, Judith, Sans, Carla, Agustí, Antonia, Blancafort, Carla Aguilar, Serrat, Gisela Gili, Plaza, Aitana, Prius, Anna Feliu, Torrens, Maria Margarita, Torres, Gloria, Calonge, Julia, Alins, Elena Ballarin, Pérez-Esquirol, Eulàlia, Bosch, Lourdes Vendrell, Aldea, Marta, Mellado, Eugènia, Marcos, Ma Ángeles, Tortajada, Marta, Barón-Mira, Lourdes E., Granés, Laura, Lazaar, Sulayman, Herranz, Sara, Malet, Montserrat, Olivé, Victoria, Gómez, Begoña, González, Elisenda, Casals, Cristina, Burunat, Laura, Castelló, Juan José, Fernández, Patricia, Vila, Jordi, Hurtado, Juan Carlos, Jado, Isabel, Fedele, Giovanni, Perea, Concepción, González, Mónica, Murillo, María Ángeles, Balfagón, Pilar, Díaz-Marín, Irene
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.09.2024; Elsevier
• Subjects: Immune response; Immunology; Immunology; Immune response
• ISSN: 2589-0042; 2589-0042
• DOI: 10.1016/j.isci.2024.110728

CombiVacS study has demonstrated a strong immune response of the heterologous ChAdOx1-S/BNT162b2 vaccine combination. The primary outcomes of the study were to assess the humoral immune response against SARS-CoV-2, 28 days after a third dose of a mRNA vaccine, in subjects that received a previous prime-boost scheme with ChAdOx1-S/BNT162b2. Secondary outcomes extended the study to 3 and 6 months. The third vaccine dose of mRNA-1273 in naive participants previously vaccinated with ChAdOx1-S/BNT162b2 regimen reached higher neutralizing antibodies titers against the variants of concern Delta and BA.1 lineage of Omicron compared with those receiving a third dose of BNT162b2 at day 28. These differences between BNT162b2 and mRNA-1273 arms were observed against the ancestral variant G614 at day 90. Suboptimal neutralizing response was observed against BQ.1.1, XBB.1.5/XBB.1.9, and JN.1 in a relevant proportion of individuals 180 days after the third dose, even after asymptomatic Omicron breakthrough infections. EudraCT (2021-001978-37); ClinicalTrials.gov (NCT04860739). [Display omitted] •Higher NT50 titers was observed in mRNA-1273 arm against Delta and BA.1 at day 28•Higher NT50 titers was observed in mRNA-1273 arm against G614 variant at day 90•Suboptimal neutralization against recent Omicron variants was observed at day 180•Asymptomatic breakthrough infections do not ensure XBB.1.5 and JN.1 neutralization Immunology; Immune response